<DOC>
	<DOCNO>NCT00454688</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy different dos asimadoline treatment patient irritable bowel syndrome .</brief_summary>
	<brief_title>Asimadoline Treatment Subjects With Irritable Bowel Syndrome</brief_title>
	<detailed_description>A randomized , dose-ranging , double-blind , placebo-controlled study design evaluate efficacy tolerability three dose level asimadoline subject IBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Males female age 1879 Must sign ICF Females childbearing potential must negative pregnancy test screening must adhere contraception throughout trial Must diagnose IBS result least 6 month , necessarily consecutive , precede 12 month recurrent symptom abdominal discomfort pain associate least 2 follow : 1 ) relieve defecation ; 2 ) onset associate change stool frequency ; 3 ) onset associate change stool form Must demonstrate willingness comply daily telephone diary entry Any subject evidence biochemical structural abnormality digestive tract comorbid illness might impact ability interpret safety efficacy data Pregnant breastfeeding female Refusal discontinue prohibit concomitant medication Use investigational drug participation investigational study within 30 day screen Inability unwillingness use touchtone telephone data entry system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Asimadoline</keyword>
</DOC>